MELBOURNE CONVENTION AND EXHIBITION CENTRE · PDF fileFightMND and the Organising ... (Speech Therapist) LinkAT ... - Do not include author names in the title or body of your abstract

www.ausmnd.com.au

MELBOURNE CONVENTION AND EXHIBITION CENTRE

March 22nd - 24t h 2018

https://ausmnd.com.au

2018 AUSTRALASIAN MND SYMPOSIUM

TABLE OF CONTENTS

2

WELCOME 3

ABOUT THE SYMPOSIUM - INVITED SPEAKERS 4

GENERAL SYMPOSIUM INFORMATION 5

REGISTRATION 6

CALL FOR ABSTRACTS - BIOMEDICAL & CLINICAL STREAMS 7

ABSTRACTS FAQs 11

PRIZES - POSTER PRIZES 12

BIOMEDICAL STREAM KEYNOTE PRESENTATIONS 14

CLINICAL STREAM KEYNOTE PRESENTATIONS 15

PROGRAM - DRAFT 16

DESTINATION - MELBOURNE 19

SPONSORSHIP AND TRADE EXHIBITION 20

JOIN US IN MELBOURNE FOR THE INAUGURAL FIGHTMND AUSTRALASIAN MOTOR NEURONE DISEASE SYMPOSIUM

FightMND and the Organising Committee takes great pleasure in invit ing you to the inaugural 2018 FightMND Australasian Motor Neurone Disease Symposium.

The symposium will provide a major forum for researchers, clinicians, and pat ients to connect, exchange ideas, and discuss clinical and research issues related to scient ific research into finding effect ive treatments for this devastat ing disease, and improving the care of those current ly fight ing the disease.

March 22nd - 24t h 2018

CONNECT. COLLABORATE. EDUCATE. INSPIRE

Don't miss this opportunity to attend and/or present on your research or MND care area of speciality at this nat ional MND meeting.

The theme of this inaugural symposium is to "Connect , Collaborate, Educate, and Inspire", with the aims of invigorat ing and growing the local MND research community, inspiring innovat ion , and helping to foster new local and internat ional collaborat ions between our researchers, clinicians, and scient ists.

3

HEADER

ABOUT THE SYMPOSIUM

The inaugural FightMND Australasian MND Symposium will feature a dynamic three day program incorporat ing a variety of keynote presentat ions from invited local and overseas MND expert researchers and clinicians, oral and poster presentat ions, t rade demonstrat ions, and networking opportunit ies

4

Professor Dom RoweMacquarie University, Australia

Professor Robert Henderson University of Queensland, Australia

Professor Naomi WrayUniversity of Queensland Australia

Assoc. Professor Paul TalmanBarwon Health, Australia

Professor Samar AounCurt in University, Australia

Professor Julian GoldAlbion Inst itute, Australia

Karol Connors (Physiotherapist )Calvary Healthcare Bethlehem, Australia

Sarah Solomon (Occupat ional Therapist )Calvary Healthcare Bethlehem, Australia

Charlene Cullen (Speech Therapist )LinkAT

Renae Knight (Occupat ional Therapist )Metro Health South QLD, Australia

Stephanie Williams (Occupat ional Therapist )Calvary Healthcare Bethlehem, Australia

Rachael Russell (Occupat ional Therapist )Calvary Healthcare Bethlehem, Australia

KEYNOTE SPEAKERS

Professor Kevin TalbotOxford University, UK

Professor Jeremy ShefnerBarrow Neurological Inst itute, USA

Professor Ammar Al-ChalabiKings College, London

Professor Don ClevelandUniversity of California, USA

Professor Kevin EgganHarvard University, USA

Professor Stanley AppelWeill Cornell Medical College, USA

Professor Michael BenatarUniversity of Miami, USA

Professor Robert BowserBarrow Neurological Inst itute, USA

Dr Lucie BruijnALSA, USA

Professor Clive SvendsenCedars Sinai, USA

Professor Luis BarbeitoInst itut Pasteur de Montvideo, Uruguay

Professor Mat thew KiernanUniversity of Sydney, Australia

Professor Steven Vucic University of Sydney, Australia

BIOMEDICAL STREAM

- Genetics and genomics- Big data analysis and management- Biomarkers- Pathophysiology / Disease mechanisms- Disease models- Neuroinflammation- Stem Cells- Preclinical drug development

The inaugural 2018 FightMND Australasian Motor Neurone Disease Symposium will be held at the Melbourne Convention and Exhibit ion Centre.

Recognised as Australasia?s Leading Meetings and Conference Centre from 2012 ? 2016 by the prest igious World Travel Awards, Melbourne Convention and Exhibit ion Centre (MCEC) connects us with everything we need for a successful event ? incredible spaces, leading technology, award-winning food and the expert ise to bring it all together. MELBOURNE , AUSTRALIA

SYMPOSIUM VENUE

DELEGATESSYMPOSIUM THEMES

CLINICAL STREAM

- Disease phenotypes and classificat ion- Disease registries- Clinical Trials and trial design- Clinical management and care- Assist ive Technology- Cognit ive change and assessment- Respiratory management- Nutrit ional management- Palliat ive and end of life care- Care giver support

It is ant icipated that between 200 to 500 delegates from Australia, New Zealand, and abroad will at tend the 2018 Australasian MND Symposium from the following professions and backgrounds:

- Clinical & laboratory MND researchers

- Neurologists- General Pract it ioners- Palliat ive care

physicians- Allied Health

professionals- Nursing staff- MND pat ients- Carers

5


Further information & online registrat ion is available online at ht tps://ausmnd.com.au/register

March 22nd - 24t h 2018

REGISTRATION

6MELBOURNE , AUSTRALIA

STUDENT - EARLY BIRD (UNTIL NOVEMBER 1ST 2017) $150 +GST

STUDENT - STANDARD REGISTRATION (FROM 2ND NOVEMBER 2017 TO JANUARY 31ST 2018)

$220 +GST

NON-STUDENT - EARLY BIRD (UNTIL NOVEMBER 1ST 2017) $250 +GST

NON-STUDENT - STANDARD REGISTRATION (FROM 2ND NOVEMBER 2017 TO JANUARY 31ST 2018)

$320 +GST

MND PATIENT - EARLY BIRD (UNTIL NOVEMBER 1ST 2017) $100 +GST

MND PATIENT - STANDARD REGISTRATION (FROM 2ND NOVEMBER 2017 TO JANUARY 31ST 2018)

$150 +GST

LATE REGISTRATION (FROM 1ST FEBRUARY 2018 TO 28TH FEBRUARY 2018)

$350 +GST

ONSITE REGISTRATION (FROM MARCH 1ST 2018) $450 +GST

SINGLE DAY REGISTRATION $150 +GST

FEES: All prices are listed in AUD

https://ausmnd.com.au/register

https://ausmnd.com.au

HEADER

CALL FOR ABSTRACTSBIOMEDICAL & CLINICAL STREAMS SUMMARY OF CONDITIONS OF ACCEPTANCEMelbourne, AustraliaMarch 22nd - 24th 2018

ABSTRACTS - BIOMEDICAL STREAM

Abstracts are now being called for oral and poster presentat ions for the Biomedical St ream of the AMNDS 2018 meeting. The organising committee encourages submissions which fall within the following themes:

- Genetics and genomics- Big data analysis and management - Biomarkers - Pathophysiology / Disease mechanisms (broad category)- Disease models- Neuroinflammation - Stem Cells - Preclinical drug development

ABSTRACTS - CLINICAL STREAM

Abstracts are now being called for oral and poster presentat ions for the Clinical St ream of the AMNDS 2018 meeting. The organising committee encourages submissions which fall within the following themes:

- Disease phenotypes and classificat ion- Disease registries- Clinical t rials and trial design - Clinical management of MND pat ients (broad category)- Assist ive technology - Cognit ive change and assessment - Respiratory management - Nutrit ional management - Palliat ive and end of life care - Carer support

PRESENTATION FORMATS

Oral platform presentat ions are 20 minutes in total length and speakers should allow for a 15 minute presentat ion followed by a 5 minute quest ion period.

Posters should be paper size A0, ( 841 x 1189mm). Please ensure that the longest side of your poster is its height, sometimes known as ?portrait? orientat ion. In other words 841mm wide (horizontally) and 1189mm metre high (vert ically).

7


- Submission of your abstract acknowledges consent to publicat ion of the abstract in the Symposium proceedings, Symposium app, and the Symposium website.

- All abstracts must be submitted online.

To submit your abstract online, head to

ht tps://app.oxfordabstracts.com/stages/198/submission

- Abstracts will be submitted under the ?oral preferred? or ?poster preferred? categories and while every effort will be made to accommodate these preferences the organising committee cannot make any guarantees.

- Authors accept ing the offer of a poster presentat ion must ensure that their poster is on display at the symposium venue at the designated t ime. The corresponding author will be not ified of the t ime slot and it must be abided by.

- Abstracts may be submitted even if previously presented at a nat ional/ internat ional meeting.

- Mult iple abstract submissions per person are allowed, but registrants can only give a maximum of two (2) oral presentat ions during the ent ire Symposium. There is no limit on the number of poster presentat ions per registrant.

- Abstracts should be submitted by the corresponding author of the abstract. The corresponding author is the ONLY person that will receive email correspondence from us.

- The email address of the corresponding author will be published with any accepted abstracts.

- The present ing author (for either an oral or poster presentat ion) will be required to register for the Symposium before submit t ing his/her abst ract in order to ensure their abstract(s) is included in the final program. Formal acceptance of an abstract is condit ional upon payment of the registrat ion fee, and abstracts will not be considered for inclusion unless the present ing author has registered to attend the Symposium.

- Please ensure you have the correct permissions to submit your abstract (eg from collaborators or funders).

- All abstracts should be submitted online via the submission portal- Abstracts must be in English, and be no longer than 500 words (excluding

t it les and references) and limited to one page only.- Tables and figures CAN NOT be included

ABSTRACT SUBMISSION GUIDELINES

8

https://app.oxfordabstracts.com/stages/198/submission


- Please only use standard abbreviat ions or define them in full. - SI units should be used - For mult iple affiliat ions use numbered superscripts. - Paragraphs should be separated by an empty line, please do not indent the first

line of a paragraph - Please note: Accuracy is the responsibility of the author, please ensure you have

proof read your document carefully. Whilst every effort will be made to ensure the reproduct ion of symbols, accuracy of symbols cannot be guaranteed in the reproduct ion.

- Abstract Tit le: Please write the t it le in sentence case (capitalising only the first word and proper nouns), do not use quotat ion marks. The t it le should be as brief as possible but long enough to indicate clearly the nature of the study. The t it le is not included in 500 word limit .

- Abstracts that merely state the results that will be presented will be subject to reject ion.

- Do not include author names in the t it le or body of your abst ract because a ?blind? reviewing process will be used. You will be asked to enter the names online during the submission process.

- All abstracts are subject to review by the Program Committee and acceptance into the program is not guaranteed.

- Avoid start ing abstracts with very basic descript ions of ALS/MND e.g. ?ALS/MND is an adult-onset, rapidly progressive neurodegenerat ive disease? as an opening sentence (this is an MND conference so this knowledge is assumed)

- Please ensure that the text of your abstract is spellchecked before it is submitted.

- Conflict of Interest Statement : If the research described in the abstract was supported by a commercial company you must indicate the company's role in analysing the data or preparing the abstract. You will be asked to declare any conflicts during the submission process.

Abstract submissions are now open

Abstract submissions close: 6.00pm December 18th 2017

Abstract presentat ion announcements: January 19th 2019

To submit an abst ract , the present ing author needs to register in full to at tend the symposium.

To register click here

ABSTRACT SUBMISSION GUIDELINES CONTINUED

9


















































































































































































































































































































































For oral or poster presentations where scientific / experimental results data is to be presented, the Committee suggests that where applicable the abstract follow the format out lined below.

- AimState concisely why the study was conducted - Case StudiesState the nature of the case study which you will be present ing

- MethodIndicate the locale, sample number (n), principal test(s) performed, and the types of stat ist ical analysis employed- ResultConfirm or refute the hypothesis, supported by stat ist ics if appropriate (p values).- ConclusionState the effect of the study on future research, pat ient management, or the understanding of basic disease processes

- References

References in the text should be cited as numbers in brackets. References should also be listed in order of citat ion at the end of the text. All authors should be quoted for papers with up to three authors; for papers with more than three authors the first three should be quoted followed by ?et al?. Incomplete references will be removed at the editor?s discret ion.

For oral or poster presentations where more general topics (e.g. The role of non-invasive vent ilat ion in MND) are to be presented, the Committee suggests that where applicable the abstract follow the format out lined below.

- AimState concisely the purpose of your presentat ion - AudienceIndicate the target audience for your presentat ion- Key messagesOutline the key messages you are aiming to cover in your oral and/or poster presentat ion- ConclusionState the impact on future pat ient management or research

- References

References in the text should be cited as numbers in brackets. References should also be listed in order of citat ion at the end of the text. All authors should be quoted for papers with up to three authors; for papers with more than three authors the first three should be quoted followed by ?et al?. Incomplete references will be removed at the editor?s discret ion.

ABSTRACT SUBMISSION GUIDELINES CONTINUED

10


How do I submit my abst ract?

Submit your abstract online through our submission portal at ht tps://app.oxfordabstracts.com/stages/198/submission.

Formal acceptance of an abstract is condit ional upon payment of the registrat ion fee, and abstracts will not be considered for inclusion unless the present ing author has registered to attend the Symposium. To submit your abstract, register to attend the Symposium - head to the registrat ion page at ht tps://ausmnd.com.au/register.

What is the abst ract submission deadline?

The closing date for abstract submission is December 18th 2017.

Do you accept encore abst racts?

Yes, you can st ill submit an abstract if the material has been presented elsewhere however you must disclose this information during the submission process. A preference will be given to abstracts for material that has not been presented before.

Do you accept late breaking abst racts?

No, there is no late breaking abstract submission.

When will I know if my abst ract has been accepted?

The abstracts will be subject to a blind review process after the submission date closes and then review by the organising committee. We ant icipate not ifying authors of acceptance / reject ion in mid January 2018.

My abst ract has been accepted but I can not at tend, what do I do?

The presentat ion can be delivered by another named author, this author must have been included on the original abstract submission. Please email [email protected] to advise of any change of presenter.

I want to withdraw my abst ract

If you wish to withdraw an abstract please contact the organising committee by email as soon as possible Please email [email protected] .

I submit ted an abst ract but the data has changed or is not available. What do I do?

Please email [email protected] to advise if you will need to withdraw or update your abstract.

When will the abst racts be published?

Abstracts will be made available electronically, via the Symposium website, and the app, short ly before the Symposium. A book of abstracts will also be available at the symposium for all paid registrants.

ABSTRACTS - FREQUENTLY ASKED QUESTIONS

11



https://ausmnd.com.au/register/




mailto:[email protected]




HEADERPRIZES - POSTERSBIOMEDICAL & CLINICAL STREAMS

Prizes will be awarded for the best poster in both the biomedical and clinical streams.

Value:

The value of each poster prize is $1,000 AUD

Eligibilit y:

The poster prizes are open to the following:

- Biomedical st ream: PhD students OR early career MND/ALS researchers ( researchers awarded their PhD within the last 5 years)

- Clinical st ream: as per Biomedical stream above but also including medical and allied health professionals working with MND/ALS pat ients.

The present ing author will be required to register for the Symposium before submit t ing his/her abst ract for considerat ion of a post prize award.

To be eligible to receive one of the poster prizes, the present ing author must select the box and confirm their eligibility (as per above) within the abstract submission portal process, to indicate that they wish to be considered for the prize.

Indicat ing that you are eligible for a poster prize will not affect your likelihood of being chosen for an oral communicat ion if you have selected the ?oral preferred? opt ion in the abstract submission process.

12

HEADERPRIZES - POSTERSBIOMEDICAL & CLINICAL STREAMS

Scoring:

The init ial stage of judging will be based on the abstracts, as submitted by the abstract submission deadline. Final judging of short listed posters will take place at the symposium and all posters will be scored using the following criteria:

Poster Design:

- Organisat ion and clarity: Is the poster content organised in a logical manner, such that experimental problem, approach and results are easily understood?

- Layout & visual impact : Is the poster layout/ look/feel well done? Is there use of appropriate font sizes, readable graphics, suitable colors, pictures etc? ?

Poster Content:

- Mot ivat ion/Background: Does the poster and the present ing author present sufficient context for the reader to understand the purpose and originality of the experiment as well as the background and motivat ion for performing the experiment or present ing the case study or topic presentat ion?

- Method: Does the poster present sufficient data on the experimental methods used for the reader to understand and judge the quality of the approach?

- Results & Discussion: Does the poster demonstrate an understanding of the significance of results presented? Presenter should provide appropriate stat ist ics as appropriate.

- Conclusions & scient ific contribut ion: Does the poster and the presening author present sufficient information and data to support the conclusion(s) of the poster? Does the results of the experiment or case study presented represent an important advance towards MND research or pat ient care and the understanding of the cause(s), disease mechanisms, potent ial t reatments, and advances to improve care of MND pat ients?

The presenter must be available at an allocated t ime to answer quest ions from the judges at the conference.

13

HEADER

BIOMEDICAL STREAM PRESENTATIONS

14

Professor Matthew Kiernan

MND in Australia - where we've been, where we are, and where we are going

Professor Jeremy Shefner

Topic TBC

Professor Ammar Al-Chalabi

Topic TBC

(Subject to change)

Professor Stanley Appel

Suppressing neuroinflammation: cell-based therapy for MND/ALS

Professor Kevin Eggan

Topic TBC

Professor Kevin Talbot

Modelling early phase pathogenesis in amyotrophic lateral sclerosis

Professor Don Cleveland

Gene silencing therapy for ALS and beyond

Professor Robert Bowser

Discovery and use of biomarkers in ALS

Professor Luis Barbeito

Pharmacological inhibit ion of CSF1R and C-kit reveals new pathogenic mechanisms in ALS

Professor Naomi Wray

Making sense of big data in in the age of - Omics MND/ALS research

Professor Steve Vucic

A Phase II double-blind, placebo controlled clinical t rial of Tecfidera in ALS

Professor Dom Rowe

A Phase I Australian clinical t rial of Copper-ATSM in MND/ALS pat ients

Professor Rob Henderson

A Phase I Australian clinical t rial of an immunotherapeutic drug in MND/ALS

Professor Julian Gold

Lighthouse Trial: A Phase II clinical t rial of Triumeq in MND/ALS pat ients


Topic TBC

Professor Clive Svendsen

Topic TBC

Professor Michael Benatar

Topic TBC

Dr Lucie Bruijn

Topic TBC

HEADER

CLINICAL STREAM PRESENTATIONS

15



Sarah Solomon

The role of the OT in the lives of people living with MND - navigat ing an ever changing level of funct ion

Stephanie Williams

An update on managing comfort and pressure care for people with MND - a holist ic approach

Karol Connors

Assist ive technology usage by people living with MND: who needs what and when?

Rachael Russell

Clinical reasoning for the implementat ion of eye gaze technology for people with MND

Charlene Cullen

Hold on to your voice: opt ions for voice banking and message banking for people with MND

Professor Samar Aoun

The palliat ive approach to caring for MND: From diagnosis to bereavement

Andrew Denton

Voluntary Assisted Dying Laws - Let 's discuss


Global MND/ALS Clinical Trials Update - what have we learned and how can we improve clinical t rial design

Professor Ammar Al-Chalabi

What causes MND? Why me?


Why havent we found a cure yet?


Stem cells in MND research & treatment - an update

(Subject to change)

HEADER

DR

AFT

PR

OG

RA

M: T

HU

RSD

AY

22

ND

MA

RC

H 2

01

8TIME THURSDAY 22ND MARCH 2018

BIOMEDICAL STREAM

7.30 AM Regist rat ion desk opens

8.30 AM Open and Welcome - joint session

8.45 AM Keynote Presentat ion - joint session

9.45 AM Morning tea break, Trade Exhibit ion

RESEARCH SESSION 1A: Neuroinflammation and Glia / Disease Mechanisms

10.15 AM Keynote Presentat ion - 35 mins


11.25 AM Plat form Presentat ions x 2 20 min each (incl. 5 minute question time)

12.05PM Lunch break, Trade Exhibit ion

RESEARCH SESSION 2A: Disease Mechanisms / Genetics / Genomics / Big Data

1.10 PM Keynote Presentat ion - 35 mins


2.20 PM Plat form Presentat ions x 4 20 min each (incl. 5 minute question time)

3.40 PM Afternoon tea break, Trade Exhibit ion


5.00 PM - 6.30PM POSTER SESSION A

Coffee, tea, and refreshments



(Subject to change)TIME THURSDAY 22ND MARCH 2018

CLINICAL STREAM


8.30 AM Open and Welcome - joint session

8.45 AM Keynote Presentat ion - joint session


CLINICAL SESSION 1B: Clinical Management of MND patients A




12.05 PM Lunch break, Trade Exhibit ion

CLINICAL SESSION 2B: Assistive Technology & Equipment


1.45PM Keynote Presentat ion - 35 mins




5.00 PM - 6.30PM POSTER SESSION A




Sarah Solomon

The role of the OT in the lives of people living with MND - navigat ing an ever changing level of funct ion

Karol Connors

Assist ive technology usage by people living with MND: who needs what and when?

Stephanie Williams

An update on managing comfort and pressure care for people with MND - a holist ic approach

Rachael Russell

Clinical reasoning for the implementat ion of eye gaze technology for people with MND

Charlene Cullen

Hold on to your voice: opt ions for voice banking and message banking for people with MND


Modelling early phase pathogenesis in amyotrophic lateral sclerosis

Professor Naomi Wray

Making sense of big data in the age of -Omics MND/ALS research

Professor Stanley Appel

Suppressing Neuroinflammation - Cell-based therapy for MND/ALS

Professor Don Cleveland

Gene silencing therapy for ALS and beyond

Professor Louis Barbeito

Pharmacological inhibit ion of CSF1R and C-kit reveals new pathogenic mechanisms in inherited ALS

HEADER

DR

AFT

PR

OG

RA

M: FR

IDA

Y 2

3R

D M

AR

CH

20

18

TIME FRIDAY 23RD MARCH 2018

BIOMEDICAL STREAM


9:00 AM Keynote Presentat ion - joint session


RESEARCH SESSION 3A: Preclinical Drug Development




RESEARCH SESSION 4A: Disease Models / Biomarkers / Stem Cells





5.00 PM - 6.30PM POSTER SESSION B

7:00 PM NETWORKING COCKTAIL FUNCTION


(Subject to change)TIME FRIDAY 23RD MARCH 2018

CLINICAL STREAM


9:00 AM Keynote Presentat ion - joint session


CLINICAL SESSION 3B: Clinical Management of MND patients B


10:50 AM Plat form Presentat ions x 4 20 min each (incl. 5 minute question time)


CLINICAL SESSION 4B: Palliative and End of Life Care . Carer support





5.00 PM - 6.30PM POSTER SESSION B

7:00 PM NETWORKING COCKTAIL FUNCTION


Professor Michael BenatarProfessor Samar Aoun

The palliat ive approach to caring for MND: From diagnosis to bereavement

Andrew Denton

Voluntary Assisted Dying Laws - Let 's discussAndrew Denton

Voluntary Assisted Dying Laws - Let 's discuss


HEADER

DRAFT PROGRAM: SATURDAY 24TH MARCH 2018 COMBINED PROGRAMCLINICAL TRIALS UPDATE & ASK THE EXPERTS

TIME SATURDAY 24TH MARCH 2018

JOINT SESSION


9:00 AM Keynote Presentat ion


JOINT SESSION: Clinical Trials and trial design update

10.15 AM Keynote Presentat ion

11.15 AM Current and Upcoming Australian MND Clinical Trials Update


2.00PM POSTER AWARDS

JOINT SESSION: Ask the Experts

2:20 PM Updates for the MND Community

3:20 PM PANEL Q & A - ASK THE EXPERTS

4:05 PM Thank you and close


(Subject to change)

Professor Steve VucicProfessor Julian GoldProfessor Dominic RoweProfessor Rob Henderson

Assoc. Professor Paul Talman

The Australian Motor Neurone Disease Registry - an update

Professor Ammar Al-Chalabi - What causes MND? Why me?Professor Kevin Talbot - Why havent we found a cure yet?Professor Kevin Eggan - Stem cells in MND research & t reatment - an update


Global MND/ALS Clinical Trials Update - what have we learned and how can we improve clinical t rial design

JOIN US FOR THE INAUGURAL FIGHTMND AUSTRALASIAN MOTOR NEURONE DISEASE SYMPOSIUM

MELBOURNE

6

Melbourne is a city that knows how to live and has been voted the "World's most livable city" for the last seven years in a row from 2011 to 2017. Choose from high-end cuisine to basement rock music gigs, plays, fest ivals and blockbuster sport ing events ? all happening across a city full of parks, gardens and historic architecture. Dive in to discover the dist inct fortes and flavours of Melbourne dest inat ions.

Spend some t ime in the city centre and you?ll discover it?s neat ly divided into lit t le pockets for you to explore. Find art , bars and restaurants up and down in the laneways, retail therapy for any budget in Bourke and Collins streets, and creat ive out lets on show in Flinders Quarter. St Kilda Road means galleries and gardens, while neighbouring Yarra Precinct and Docklands deliver waterside views by the boat load.

Just a tram ride away, the eclect ic neighbourhoods on the city fringe offer endless possibilit ies. Take your fixie for a spin in the tooth-achingly cool northern suburbs Collingwood, Fitzroy, Brunswick and Northcote. Flex your plast ic in retail meccas South Yarra, Prahran and Toorak. Take your beach towel (or yacht) to bayside St Kilda, Port Melbourne and South Melbourne, and go west for more fabulous food and beaches.

Find out more about what Melbourne has to offer : ht tp://www.visitmelbourne.com/Regions/Melbourne

19

http://www.visitmelbourne.com/Regions/Melbourne


March 22nd - 24t h 2018

SPONSORSHIP AND TRADE EXHIBITION

20MELBOURNE , AUSTRALIA

Don't miss this opportunity to showcase your organisat ion at this nat ional MND meeting.

Becoming a part of our symposium helps build your brand, strengthens the MND research and pat ient care industry, creates unique relat ionships, provides networking opportunit ies, and allows you to demonstrate your commitment to improving the lives

of MND pat ients.

DOWNLOAD SPONSORSHIP AND TRADE EXHIBITION PROSPECTUS

https://ausmnd.com.au/wp-content/uploads/AMNDS-Sponsorship-Prospectus.pdf







REGISTERED AUSTRALIAN CHARITY

ACNC: 62 740 350 704PO BOX 23390, DOCKLANDS, VIC, 8012

[email protected]


https://fightmnd.org.au


Documents

MELBOURNE CONVENTION AND EXHIBITION CENTRE · PDF fileFightMND and the Organising ... (Speech Therapist) LinkAT ... - Do not include author names in the title or body of your abstract